Oslo Universitetssykehus HF
- Address
- lock Available on a paid plan
Hematologic Oncology
The Dept. of Hematology at Oslo University Hospital conducts extensive research on blood‑cancer disorders such as leukemia, lymphoma and multiple myeloma, aiming to test innovative targeted agents and improve stem‑cell transplant outcomes.
- Acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Mantle cell lymphoma
- Plasma cell myeloma
- Myelodysplastic syndromes
Trials evaluate safety, efficacy and biomarkers to personalize therapy for patients with high‑risk hematologic malignancies.
Solid Tumor Oncology
Research spans major solid cancers, including non‑small cell lung cancer, breast cancer, melanoma and gastrointestinal malignancies, with a focus on novel immunotherapy combinations and precision‑medicine approaches.
- Advanced NSCLC with EGFR or KRAS mutations
- HER2‑positive breast cancer
- Metastatic melanoma
- KRAS‑mutant colorectal cancer
- Gastrointestinal stromal tumor (KIT‑mutated)
The goal is to enhance survival and quality of life by integrating targeted drugs, checkpoint inhibitors and anti‑angiogenic agents.
Cardiovascular & Metabolic Research
The site advances care for cardiovascular conditions such as atherosclerotic cardiovascular disease and atrial fibrillation, while also addressing metabolic disorders like type‑2 diabetes and familial hypercholesterolemia.
- Aortic stenosis
- Persistent atrial fibrillation
- Chronic heart failure
- Familial hypercholesterolemia
- Type‑2 diabetes mellitus
Ongoing studies compare antithrombotic strategies, evaluate new lipid‑lowering therapies and explore metabolic control to reduce cardiovascular risk.
Immune‑Mediated & Inflammatory Diseases
A broad portfolio targets autoimmune and inflammatory disorders, including Crohn’s disease, ulcerative colitis, systemic lupus erythematosus and skin conditions such as hidradenitis suppurativa.
- Crohn’s disease
- Ulcerative colitis
- Systemic lupus erythematosus
- Psoriatic arthritis
- Hidradenitis suppurativa
Trials aim to determine the effectiveness of new biologics, JAK inhibitors and other immune‑modulating agents in achieving remission and improving patient outcomes.
Neurological & Neurodegenerative Disorders
The department investigates brain and nerve diseases, focusing on Alzheimer’s disease, amyotrophic lateral sclerosis and multiple sclerosis, with the purpose of testing disease‑modifying therapies and supportive interventions.
- Alzheimer’s disease
- Amyotrophic lateral sclerosis
- Multiple sclerosis
- Narcolepsy with cataplexy
- Cognitive impairment
Research evaluates safety, functional benefits and biomarkers to guide future treatment strategies for neurodegenerative conditions.
Pediatric Rare & Genetic Disorders
Specialized studies address rare childhood diseases such as achondroplasia, ataxia‑telangiectasia, Duchenne muscular dystrophy and high‑risk neuroblastoma, seeking novel gene‑targeted and enzyme‑replacement approaches.
- Achondroplasia
- Ataxia telangiectasia
- Duchenne muscular dystrophy
- High‑risk neuroblastoma
- PIK3CA‑related overgrowth spectrum
Early‑phase trials assess safety, tolerability and preliminary efficacy of emerging therapies for these genetically driven conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 35 therapeutic areas and 15 of 565 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 543 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 112 by active trials.
- 1Oslo University Hospital HF47active
lock +111 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF69trials
lock +66 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oslo Universitetssykehus HF
lock Showing 1 of 472 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 565 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 41 | Unknown | 2016-07-15 | 2026-07-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.